Items Tagged ‘tafinalr’

October 8th, 2014

COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma


For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer each year, roughly 68,000 involve melanoma. More than 8,000 people die of melanoma each […]

View full entry

Tags: Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, tafinalr, trametinib, zelboraf